Last reviewed · How we verify
NCT06369935
A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.
trial testing Equecabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma in 260 participants. Not yet recruiting.
20 August 2026
Quick facts
| Lead sponsor | Peking University People's Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 260 |
| Start date | 20 June 2024 |
| Primary completion | 20 August 2026 |
| Estimated completion | 20 August 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Equecabtagene Autoleucel — full drug profile →
Conditions studied
- Relapsed/Refractory Multiple Myeloma — all drugs for Relapsed/Refractory Multiple Myeloma →
Sponsor
Peking University People's Hospital
Who can join
18 and older, any sex, with Relapsed/Refractory Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a multicenter, observational, single-arm real world study. The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in China with relapsed/refractory multiple myeloma (RRMM) who have been treated with Equecabtagene Autoleucel. This study will use both prospective and retrospective data
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06369935
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Relapsed/Refractory Multiple Myeloma
Currently open trials in the same condition.
- NCT07493135 — A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma · EARLY_PHASE1 · recruiting
- NCT07509086 — IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia · Phase 2 · recruiting
- NCT06730256 — A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia · EARLY_PHASE1 · recruiting
- NCT06669247 — A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants · Phase 1, PHASE2 · recruiting
- NCT06718270 — a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia · EARLY_PHASE1 · recruiting
Other Peking University People's Hospital trials
Trials by the same sponsor.
- NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
- NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
- NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
- NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06369935 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
- Last refreshed: 17 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06369935.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing